BioSpace News Archive

Hummingbird Bioscience, an innovative clinical-stage biotech company focused on developing precision therapies against hard-to-drug targets announced that its abstract reporting pre-clinical results from its V-domain immunoglobulin suppressor of T cell activation antibody, HMBD-002, has been selected for publication at the American Society of Clinical Oncology Annual Meeting, to be held June 4-8, 2021.

QYNAPSE Inc., an AI neuroimaging medical technology company, joins the global multiple sclerosis community in recognition of World MS Day to raise awareness for everyone affected by MS. Emphasizing the World MS Day 2021 theme, MS Connections, Qynapse has been engaged for years in contributing to connect MS patients to MS research, especially in the field of neuroimaging innovation.

As nature springs to life and warmer weather sets in across Canada, it is hard not to feel the excitement that the summer season typically brings.

Nexturn Bio Inc., a subsidiary of Nexturn Bioscience Co., Ltd., announced on May 26th that it had acquired a 50% stake in RosVivo Therapeutics Inc., an American new drug developer, for about 5.5 million U.S. dollars.